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IMPORTANCE Aortic stenosis (AS) has no approvedmedical treatment. Identifying etiological
pathways for AS could identify pharmacological targets.
OBJECTIVE To identify novel genetic loci and pathways associated with AS.
DESIGN, SETTING, AND PARTICIPANTS This genome-wide association study used a case-control
design to evaluate 44 703 participants (3469 cases of AS) of self-reported European ancestry
from the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort (from
January 1, 1996, to December 31, 2015). Replication was performed in 7 other cohorts totaling
256926 participants (5926 cases of AS), with additional analyses performed in 6942
participants from the Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) Consortium. Follow-up biomarker analyses with aortic valve calcium (AVC) were
also performed. Data were analyzed fromMay 1, 2017, to December 5, 2019.
EXPOSURES Genetic variants (615 643 variants) and polyunsaturated fatty acids (ω-6 and ω-3)
measured in blood samples.
MAIN OUTCOMES ANDMEASURES Aortic stenosis and aortic valve replacement defined by
electronic health records, surgical records, or echocardiography and the presence of AVC
measured by computed tomography.
RESULTS Themean (SD) age of the 44 703 GERA participants was 69.7 (8.4) years, and
22019 (49.3%) weremen. The rs174547 variant at the FADS1/2 locus was associated with
AS (odds ratio [OR] per C allele, 0.88; 95% CI, 0.83-0.93; P = 3.0 × 10−6), with genome-wide
significance after meta-analysis with 7 replication cohorts totaling 312 118 individuals (9395
cases of AS) (OR, 0.91; 95% CI, 0.88-0.94; P = 2.5 × 10−8). A consistent association with AVC
was also observed (OR, 0.91; 95% CI, 0.83-0.99; P = .03). A higher ratio of arachidonic acid to
linoleic acid was associated with AVC (OR per SD of the natural logarithm, 1.19; 95% CI,
1.09-1.30; P = 6.6 × 10−5). In mendelian randomization, increased FADS1 liver expression and
arachidonic acid were associated with AS (OR per unit of normalized expression, 1.31 [95% CI,
1.17-1.48; P = 7.4 × 10−6]; OR per 5–percentage point increase in arachidonic acid for AVC, 1.23
[95% CI, 1.01-1.49; P = .04]; OR per 5–percentage point increase in arachidonic acid for AS,
1.08 [95% CI, 1.04-1.13; P = 4.1 × 10−4]).
CONCLUSIONS AND RELEVANCE Variation at the FADS1/2 locus was associated with AS and
AVC. Findings from biomarker measurements andmendelian randomization appear to link
ω-6 fatty acid biosynthesis to AS, whichmay represent a therapeutic target.
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A ortic stenosis (AS) remains the leading cause of clini-cal valve disease in the developedworld.1 Contempo-rary treatment is limited to replacement of the aortic
valve, becauseno approvedmedical therapy currently exists.
The development of such therapy would expand options for
treating AS but is hindered by a limited understanding of the
causal contributors.
Agenome-wideassociationstudy (GWAS)conducted in the
Cohorts for Heart and Aging Research in Genomic Epidemiol-
ogy (CHARGE) Consortium demonstrated that the LPA locus
(OMIM 152200),which codes for the apolipoprotein(a)moiety
of lipoprotein(a), is causally associated with incident AS and
prevalent aortic valve calcium (AVC), a subclinical phenotype
that precedes AS.2 This association with AS has been robustly
confirmedinmultiplecohorts.3-5Recentclinical trialshavedem-
onstrated that significant reductions in lipoprotein(a) levels are
achievable,6-8whichmayrepresentanovelASpreventionstrat-
egy.TworecentGWAS(≤2457casesofAS)have identifiedTEX41
and PALMD variants as associatedwith AS, implicating abnor-
mal cardiac development in disease etiology.9,10
A GWAS with a greater number of cases could have im-
proved statistical power todiscover additional genetic loci for
ASand identifynovelpathwaysaspharmacological targets.Ac-
cordingly,weperformedaGWAS forAS among44703partici-
pants (3469 cases of AS) from the Genetic Epidemiology Re-
search on Adult Health and Aging (GERA) cohort, one of the
largest collections of AS cases in the world. We validated our
findings in 7 additional cohorts totaling 256926 participants
(5926 cases of AS) and performed genetic and plasma bio-
markeranalyses todescribeanovelmechanismunderlyingAS,
with potential therapeutic implications. An overview of the
study is given in eFigure 1 in the Supplement.
Methods
Genetic Discovery and Replication
In the GERA cohort (NCBI Database of Genotypes and Pheno-
types, phs000788.v2.p3), we performed a GWAS for preva-
lent AS (615643 variants), adjusting for age, age squared, and
sex, among 44703 unrelated individuals of self-reported Eu-
ropean ancestry, 55 years or older (eTable 1 in the Supple-
ment).We restrictedour analysis toEuropeanparticipantsow-
ing to the small numbers of non-EuropeanGERAparticipants,
because differences in genetic structure between ancestries
may confound our findings. Aortic stenosis status was ascer-
tained through electronic health records (January 1, 1996, to
December 31, 2015, inclusive), using the International Classi-
fication ofDiseases, 9thRevision, diagnosis code forAS (ICD-9)
(424.1) or aprocedurecode for aortic valve replacement todes-
ignate cases; all other individuals were designated as con-
trols. Individualswithcongenital valvulardisease (ICD-9codes
746-747)were excluded.Details of this case-control study are
given ineMethods intheSupplement.Allparticipantshavepro-
videdwritten, informed consent, and all relevant internal re-
view boards approved this study. This study followed the
Strengthening the Reporting of Genetic Association Studies
(STREGA) reporting guideline.
We later received updated GERA data for 55 192 unre-
lated participants of European-ancestry 55 years and older
(3469 cases of AS). Owing to a small number of participants
who withdrew consent after our initial analysis, the compo-
sitionof the cases changed slightly, but the significant change
was the addition of 10489 controls. We imputed the 1 region
that contained a variant demonstrating a novel, potential
association with AS (P ≤ 1 × 10−6) (eMethods in the Supple-
ment) and reassessed the association of the variant with AS,
first adjusted for age, age squared, and sex, and then further
adjusted for (1) dyslipidemia, hypertension, smoking (ever or
never), and diabetes; (2) the LPA variant rs10455872; or (3) 10
principal components in separatemodels. In 7 replication co-
horts totaling256926participants (5926casesofAS) (eTable2
in the Supplement),we estimated the association of this vari-
antwithAS.Toassess theoverall associationof thevariantwith
AS, we performed a fixed-effects meta-analysis using esti-
mates fromdiscoveryand replicationcohorts,weightedby the
inverse of their variance. As a sensitivity analysis, we per-
formeda fixed-effectsmeta-analysisusingestimates fromonly
the replication cohorts.
In the CHARGE Consortium, we estimated the associa-
tion of the variant with prevalent AVC among 6942 predomi-
nantly European participants (2245 participants with AVC).
Aortic valve calcium was quantified using computed tomog-
raphy and dichotomized into presence (Agatston score >0) or
absence (Agatston score = 0) ofAVC (eMethods in the Supple-
ment). We also identified previously reported, genome-wide
significant associations with PhenoScanner11 (retrieved Sep-
tember 23, 2018) and accessed results for this variant in a
GWAS for coronary artery disease (CARDIoGRAMplusC4D
consortium).12
Associations of Fatty Acid LevelsWith AS and AVC
To investigate mediation of the lead variant through polyun-
saturated fatty acid biosynthesis, we estimated the associa-
tions of 4 polyunsaturated fatty acids (arachidonic acid, lin-
oleic acid, eicosapentaenoic acid, and α-linolenic acid) and
2polyunsaturated fatty acid ratios reflecting fatty aciddesatu-
ration activity (ratio of arachidonic acid to linoleic acid and
Key Points
Question Can genetic analysis identify additional causes of aortic
stenosis?
Findings In this genome-wide association study of 44 703
participants, each copy of a FADS1/2 (fatty acid desaturase) genetic
variant was associated with a 13% decrease in the odds of aortic
stenosis. Results of a meta-analysis with 7 replication cohorts
showed genome-wide significance, with biomarker andmendelian
randomization analyses implicating elevated ω-6 fatty acid levels
as having a potentially causal association with aortic valve calcium
and aortic stenosis.
Meaning These findings demonstrate that the FADS1/2 locus and
fatty acid biosynthesis are associated with aortic stenosis and
should be examined further for their potential as therapeutic
targets.
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ratio of eicosapentaenoic acid to α-linolenic acid)withAVC in
the FraminghamOffspring Study (FOS) cohort (n = 1310 [492
casesofAVC])andEuropean-ancestryparticipants in theMulti-
Ethnic Study of Atherosclerosis (MESA) cohort (n = 2415 [387
cases of AVC]) (eMethods in the Supplement), because mea-
surements of fatty acid levels were unavailable in the GERA
cohort.Wealsoassessedwhether theassociationofdietary lin-
oleic acidorα-linolenicacidwith incidentAS in theMalmöDiet
and Cancer Study cohort and prevalent AVC in the FOS and
MESA cohorts wasmodified by our lead variant (eMethods in
the Supplement).
Mendelian Randomization of Arachidonic Acid, FADS1
Expression, and FADS2 ExpressionWith AS and AVC
Using mendelian randomization, we estimated the associa-
tionof aplasmaarachidonic acid genetic risk scorewithAS (32
variants [eTable 3 in the Supplement]) and AVC (24 variants
[eTable 4 in the Supplement]). Additional sensitivity analy-
seswere (1) removalof the leadvariantand (2) inversevariance-
weighted, penalized weighted median, and Egger extension
methods to assess for robustness of the findings. We also as-
sessed whether elevated FADS1 (OMIM 606148) and FADS2
(OMIM 606149) expression in the liver was causally associ-
ated with prevalent AS (5 variants for FADS1 [eTable 5 in the
Supplement]) and AVC (6 variants for FADS1 [eTable 6 in the
Supplement])usingmendelian randomization.Details arepro-
vided in the eMethods in the Supplement.
Statistical Analyses
Data were analyzed from May 1, 2017, to December 5, 2019.
Genome- and locus-wide genetic associations in the GERA
cohort were computed using PLINK, version 2.0.13 The asso-
ciations of fatty acids with AVC in the MESA and FOS cohorts
were estimated using R, version 3.5.1 (R Project for Statistical
Computing), and SAS, version 9.4 (SAS Institute, Inc),
respectively. Meta-analyses of the lead variant and mende-
lian randomization analyses were performed using R, ver-
sion 3.5.1. Two-sided P ≤ 5 × 10−8 was deemed significant in
the GWAS, and 2-sided P ≤ .05 was considered significant in
other analyses.
Results
Association of the FADS1/2 LocusWith AS and AVC
Thediscoverycohortof44703participants consistedof22019
men (49.3%) and22684women (50.7%),with amean (SD) age
of 69.7 (8.4) years. We found no evidence of inflated test sta-
tistics in theGWAS forAS (genomic inflation factor, 1.03 [eFig-
ure 2 in the Supplement]).We confirmed the associations pre-
viously reported for LPA and PALMD variants (eTable 7 in the
Supplement).The intronicvariant rs174547at theFADS1/2 (fatty
acid desaturase 1 and 2) locus on chromosome 11 was the only
variant that demonstrated a novel association with AS at
P ≤ 1 × 10−6 (Figure1),witheachcopyof theminor (C)allele (fre-
quency, 33%) conferring 13% lower odds ofAS (odds ratio [OR]
perminor allele, 0.87; 95%CI, 0.83-0.92; P = 8.5 × 10−7). After
imputation of the locus in the larger set of GERA participants,
the associationof rs174547withASwas essentially unchanged
(OR per minor allele, 0.88; 95% CI, 0.83-0.93; P = 3.0 × 10−6),
withvariants inhigh linkagedisequilibriumalsoassociatedwith
AS (eFigure 3 in the Supplement). Further adjustment for car-
diovascular risk factors, the LPA variant rs10455872, or popu-
lation substratification did not materially change these esti-
mates (eTable 8 in the Supplement). Participants who were
homozygousfortheminorallele(6182of55192[11.2%])had26%
lower odds of AS (OR, 074; 95% CI, 0.65-0.84; P = 2.8 × 10−6)
relative to participants homozygous for the major allele, ad-
justed for age, age squared, and sex.
When we combined this result with findings from 7
replication cohorts in a meta-analysis totaling 312 118 indi-
viduals (9395 cases of AS), the overall association reached
Figure 1. PValues for the Association of 615 643 Genetic VariantsWith Aortic Stenosis
in the Genetic Epidemiology Research on Adult Health and Aging Cohort by Chromosome
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The red line indicates genome-wide
significance (P  5 × 10−8); the blue
line, suggestive evidence of
association (5 × 10−8<P  1 × 10−6).
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genome-wide significance (OR perminor allele, 0.91; 95%CI,
0.88-0.94; P = 2.5 × 10−8) (Figure 2), and we observed no
heterogeneity in the estimates (I2 = 0%). When only the rep-
lication cohorts were meta-analyzed, the magnitude of asso-
ciationwas similar and significant (OR perminor allele, 0.93;
95% CI, 0.89-0.97; P = 7.4 × 10−4), and there remained no
heterogeneity (I2 = 0%).
The rs174547 variant demonstrated a consistent associa-
tion with AVC in the CHARGE consortium (OR per minor al-
lele, 0.91; 95% CI, 0.83-0.99; P = .03). Results accessed from
PhenoScanner (eTable9 in theSupplement) indicated that this
variant was also associated with other biochemical pheno-
types, including fatty acid and lipidmeasures, but only 1 dis-
ease entity, asthma, which is characterized by eicosanoid-
mediated inflammation. In the CARDIoGRAMplusC4D
consortium, therewasanominally significant associationwith
coronary artery disease (OR per minor allele, 0.98; 95% CI,
0.96-1.00; P = .03).
Associations of Fatty Acid Levels
With AS and AVC
Due to the role of the FADS1/2 locus in ω-6 and ω-3 fatty acid
biosynthesis (Figure 3), we examined the association of ω-6
and ω-3 fatty acids as well as fatty acid ratios reflecting ω-6
and ω-3 desaturation activity with AVC in the FOS and MESA
cohorts (Table 1 and eTable 10 in the Supplement). Higher
levels of arachidonic acid and a higher ratio of arachidonic
acid to linoleic acid, reflecting increased conversion of lin-
oleic acid to arachidonic acid, were associated with
increased odds for AVC, adjusted for age and sex (combined
OR per SD of the natural logarithm of arachidonic acid levels,
1.12 [95% CI, 1.03-1.22; P = .01]; combined OR per SD of the
natural logarithm of the ratio, 1.19 [95% CI, 1.09-1.30;
P = 6.6 × 10−5]). These associations were materially
unchanged after adjustment for low-density lipoprotein cho-
lesterol level, systolic blood pressure, smoking, and diabetes
(Table 1). Neither eicosapentaenoic acid nor the ratio of
eicosapentaenoic acid to α-linolenic acid, reflecting
increased conversion of α-linolenic acid to eicosapentaenoic
acid, were associated with AVC. We did not observe interac-
tions between dietary linoleic acid and rs174547 for their
associations with incident AS or prevalent AVC (eTables 11
and 12 in the Supplement).
Mendelian Randomization of Arachidonic Acid Level
and FADS1 ExpressionWith AS and AVC
Toevaluatepotential causalityofω-6 fattyacids inASandAVC,
we used mendelian randomization to estimate the associa-
tionsbetweenaplasmaarachidonic acidgenetic risk score and
AS and AVC separately. Genetically elevated arachidonic acid
level was associated with a higher prevalence of AS and AVC,
with a 5–percentage point increase of arachidonic acid level
among total fatty acids corresponding to an8% increase in the
odds for AS (OR, 1.08; 95% CI, 1.04-1.13; P = 4.1 × 10−4) and a
23% increase in the odds for AVC (OR, 1.23; 95% CI, 1.01-1.49;
P = .04). In sensitivity analyses excluding the rs174547 vari-
ant or accounting for the effects of the genetic risk score
Figure 3. Roles of FADS1 and FADS2 in the Conversion of 18-Carbon ω-6
and ω-3 Fatty Acids to Arachidonic and Eicosapentaenoic Acids
ω-6 Fatty acids
Linoleic acid
18:2ω-6
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18:4ω-3
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FADS1 and FADS2 perform the desaturation steps in the conversion of
18-carbon ω-6 and ω-3 fatty acids to arachidonic and eicosapentaenoic acids.
Figure 2. Association of FADS1/2 rs174547With Aortic Stenosis (AS) in the Discovery and Replication Cohorts
P Value
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Favors Higher
Risk of AS
0.7 21
OR per Minor Allele (95% CI)
No. of
Cases
No. of
ControlsCohort
Discovery
OR per Minor
Allele (95% CI)
Heterogeneity: I2 = 0% (95% CI, 0%-66%); P = .47
3.0 × 10–63469 51 723GERA 0.88 (0.83-0.93)
3.0 × 10–6Discovery cohort effect 0.88 (0.83-0.93)
7.4 × 10–4Replication fixed-effects model 0.93 (0.89-0.97)
2.5 × 10–8Overall fixed-effects model 0.91 (0.88-0.94)
Replication
.021009 1017QUEBEC-CAVS 0.85 (0.74-0.98)
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.281593 4550PMBB 0.95 (0.86-1.04)
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.54218 436Umeå University 1.08 (0.84-1.39)
For rs174547, C and T are theminor
andmajor alleles, respectively. The
sizes of the dark blue squares reflect
the weight of the cohorts in the
fixed-effects meta-analysis.
BioVU indicates Vanderbilt DNA
Biobank; EPIC-Norfolk, European
Prospective Investigation of Cancer
and Nutrition–Norfolk; GERA, Genetic
Epidemiology on Adult Health and
Aging; MDCS, Malmö Diet and Cancer
Study; NA, not applicable; OR, odds
ratio; PMBB, PennMedicine BioBank;
and QUEBEC-CAVS, Quebec City
Case-Control Calcific Aortic Valve
Stenosis.
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throughmechanisms other than arachidonic acid (ie, genetic
pleiotropy), we observed attenuation under some conditions
(Table 2), although the intercept in the Egger regressionswas
not significant.
Mendelian randomization analysis also indicated that ge-
netically elevated FADS1 expression in the liver conferred
increased odds of AS (OR per unit increase of normalized
expression, 1.31; 95%CI, 1.17-1.48;P = 7.4 × 10−6) andAVC (OR
perunit increaseof normalizedexpression, 1.25; 95%CI, 1.02-
1.52;P = .03). Sensitivity analyses supportedapotential causal
associationofelevatedFADS1expressionwithASandAVC,with
noevidenceof directional pleiotropy (eTable 13 in the Supple-
ment).No significantFADS2 liver expressionquantitative trait
loci were available.
Discussion
We conducted a GWAS for AS in the GERA cohort, with one of
the largest collectionsof cases ofAS todate. TheFADS1/2vari-
ant rs174547demonstratedassociationwithprevalentAS,with
each copy of theminor allele conferringmore than 10% lower
odds of the disease. In individuals homozygous for theminor
allele,we observed a 26% reduction in the odds of AS. The as-
sociationpersisted after adjustments forLPA rs10455872, car-
diovascular risk factors, orpopulation stratification.When the
discovery and 7 replication cohorts consisting of 312 118 indi-
viduals (9395 cases of AS) were combined, rs174547 reached
genome-wide significance. The association also persisted in
a sensitivity analysis excluding thediscovery cohort, support-
ing a robust associationwithAS.The rs174547variantwas also
associatedwithprevalentAVCin theCHARGEconsortium,pro-
viding additional evidence for a role in early valvular calcifi-
cation. Because the FADS1/2 locus is a key regulator of poly-
unsaturated fatty acid biosynthesis,14 we assessed the
association of several ω-6 and ω-3 fatty acid levels with AVC.
Increased production of theω-6 arachidonic acid, but not the
ω-3 eicosapentaenoic acid, was associated with AVC, with
highly consistent results in2cohorts.We furtherobserved that
genetically elevated FADS1 expression in the liver was asso-
ciatedwith increased odds of AS andAVC.Additionalmende-
lian randomization analyses provided evidence of a poten-
tially causal associationbetweenplasmaarachidonic acid, the
product of the ω-6 pathway, and both AS and AVC, although
we were unable to entirely exclude the possibility of pleiot-
ropy. Therefore, our results indicate that FADS1/2 variation is
a key determinant of valve calcification, demonstrate that
plasmaω-6 fatty acids are associatedwith valve calcium, and
suggest that increased ω-6 fatty acid biosynthesis may be a
causal pathway for AS.
Table 2. Genetic Associations of Arachidonic AcidWith Aortic Stenosis
and Aortic Valve Calcium
Method
OR per 5–Percentage Point
Increase of AA Among
Total Fatty Acids (95% CI) P Value
Aortic Stenosis
Mendelian randomization 1.08 (1.04-1.13) 4.1 × 10−4
Excluding rs174547a 1.03 (0.99-1.08) .15
Inverse variance-weighted 1.08 (1.02-1.15) 8.9 × 10−3
Penalized weighted median 1.11 (1.03-1.20) 4.9 × 10−3
Egger extension to mendelian
randomization
1.02 (0.92-1.13) .72
Intercept for the Egger
extension
NA .15
Aortic Valve Calcium
Mendelian randomization 1.23 (1.01-1.49) .04
Excluding rs174547a 1.10 (0.82-1.49) .52
Inverse variance-weighted 1.23 (1.01-1.49) .04
Penalized weighted median 1.32 (1.04-1.68) .02
Egger extension to mendelian
randomization
1.08 (0.78-1.49) .63
Intercept for the Egger
extension
NA .32
Abbreviations: AA, arachidonic acid; NA, not applicable; OR, odds ratio.
a Genetic risk score is not associated with eicosapentaenoic acid.
Table 1. Associations of ω-6 and ω-3 Fatty AcidsWith Aortic Valve Calciuma
Fatty Acid Cohort
Adjusted for Age and Sex Fully Adjustedb
OR (95% CI) P Value OR (95% CI) P Value
ω-6
AA level
FOS 1.10 (0.97-1.25) .13 1.13 (0.98-1.29) .09
MESA 1.13 (1.01-1.27) .04 1.14 (1.01-1.29) .03
Combined 1.12 (1.03-1.22) .01 1.14 (1.04-1.24) 5.8 × 10−3
AA:LA
ratio
FOS 1.20 (1.06-1.37) 5.2 × 10−3 1.22 (1.06-1.39) 4.6 × 10−3
MESA 1.19 (1.06-1.34) 4.4 × 10−3 1.22 (1.08-1.38) 1.6 × 10−3
Combined 1.19 (1.09-1.30) 6.6 × 10−5 1.22 (1.11-1.34) 2.2 × 10−5
ω-3
EPA level
FOS 0.91 (0.80-1.04) .16 0.91 (0.80-1.04) .18
MESA 1.04 (0.92-1.16) .54 1.07 (0.95-1.21) .25
Combined 0.98 (0.90-1.07) .63 1.00 (0.91-1.09) .97
EPA:ALA
ratio
FOS 0.99 (0.87-1.12) .85 1.00 (0.88-1.15) .95
MESA 1.08 (0.96-1.22) .19 1.12 (0.99-1.26) .08
Combined 1.04 (0.95-1.13) .40 1.06 (0.97-1.16) .18
Abbreviations: AA, arachidonic acid;
ALA, α-linolenic acid;
EPA, eicosapentaenoic acid;
FOS, FraminghamOffspring Study;
LA, linoleic acid; MESA, Multi-Ethnic
Study of Atherosclerosis;
OR, odds ratio.
a The ORs are calculated per SD of the
natural logarithm for AA and EPA
and per SD of the natural logarithm
of the ratio of the fatty acids for the
AA:LA and EPA:ALA ratios.
Estimates were combined via
fixed-effects meta-analysis
weighted by the inverse of their
variance.
bAdjusted for low-density lipoprotein
cholesterol level, systolic blood
pressure, current smoking, and
diabetes, in addition to age and sex.
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The rs174547 variant is located in an intron of FADS1, a
member of theFADS1/2/3 gene cluster. The functionofFADS3
is unknown, whereas FADS1 and FADS2 encode fatty acid de-
saturases with key functions in the conversion of dietary lin-
oleic andα-linolenic acids into arachidonic andeicosapentae-
noic acids, respectively (Figure 3).14 Notably, the rs174547
variant resides on a haplotype that extends across FADS1 and
part of FADS2, and the minor allele is associated with de-
creased transcription ofFADS1 and increased transcription of
FADS2 across most tissue types.15 The net result is lower ara-
chidonic acid levels and higher linoleic acid levels,16,17 indi-
cating that the conversion of dietaryω-6 fatty acids to longer-
chain polyunsaturated fatty acids is less active inminor allele
carriers. The minor allele is also associated with lower levels
of eicosapentaenoicacidandhigher levelsofα-linolenicacid,18
mirroring theeffectsobservedforω-6 long-chain fattyacidsyn-
thesis. However, the conversion of α-linolenic acid to down-
streamproducts is inefficient, and levelsof long-chainω-3 fatty
acids arehighlydependentondiet.19Arachidonic acid is apre-
cursor for proinflammatory prostaglandins and leukotrienes,
whereas leukotrienes and resolvins derived from eicosapen-
taenoic acid are anti-inflammatory,20 and thus the enzymatic
activities of FADS1 and FADS2 proteins may have proinflam-
matory and anti-inflammatory effects.
Although higher linoleic acid levels have been associated
with reduced risk of all-cause mortality and myocardial
infarction,21 many prior studies have not evaluated the con-
tributionof the ratioof arachidonic to linoleic acid (orFADS1/2
genotypes), thereby overlooking interindividual variation in
the production of arachidonic acid. A ratio of higher arachi-
donic acid to linoleic acidhas been associatedwith cardiovas-
cularandall-causemortalityafteradjustment for risk factors,22
which suggests that FADS1 andFADS2protein activitymay in-
dependently contribute to cardiovascular outcomes.
Several lines of evidence point to ω-6 fatty acids as pos-
sible causal mediators for AS. We found that a higher ratio of
arachidonic acid to linoleic acid (reflecting ω-6 desatura-
tion), but not the ratio of eicosapentaenoic acid to α-linolenic
acid (reflecting ω-3 desaturation), was associated with AVC.
This finding is consistent with ourmendelian randomization
findings, which demonstrate that genetically elevated FADS1
expression, as well as arachidonic acid levels, were associ-
ated with AS and AVC, providing evidence of a causal link. A
greater conversion of linoleic acid to arachidonic acidmay be
associated with a local proinflammatory state via increased
leukotrienes.23,24 Increased inflammation has been demon-
strated among patients with AS, as denoted by overexpres-
sion of interleukin-625 and interleukin-1β26 at the valve. In-
deed, local levels of leukotrienes B4 and C4, downstream
metabolites of arachidonic acid, are associated with the ex-
tent of valve calcification27 and aortic valve area,25 providing
amechanistic linkbetweenproductionof arachidonic acidand
valve calcification and AS. Higher levels of arachidonic acid
in phospholipids, observed in explanted stenotic aortic
valves,28mayalso increase their susceptibility tooxidationand
promote local inflammation and subsequent calcification.
Linking variation at the FADS1/2 locus to AS is compli-
cated by the multitude of identified biomarker associations,
whichareall likelysecondary topolyunsaturated fattyacidbio-
synthesis. Theassociationof rs174547withAS in theGERAco-
hort persisted when adjusted for dyslipidemia, hyperten-
sion, smoking, anddiabetes. In theFOSandMESAcohorts, the
associationbetweenAVCandgreaterconversionof linoleicacid
to arachidonic acid also remained after adjustment for low-
density lipoprotein cholesterol level, systolic blood pressure,
smoking, anddiabetes. Thus, the associationsof rs174547 and
increasedarachidonicacidwithaorticvalveoutcomesare likely
to be independent of the effects of rs174547 on these risk fac-
tors. Our mendelian randomization of FADS1 expression fur-
ther demonstrates the key role of FADS1 and implicates fatty
aciddesaturation invalvecalcification.Finally,mendelian ran-
domization analyses for arachidonic acidwere robust to plei-
otropyunder certain assumptions suchaspenalizedweighted
median, which allows for as many as 50% of the variants in
the genetic risk score to be pleiotropic. Because the intercept
did not differ significantly from zero in our Egger regression
forASorAVC,nostrongevidenceof alternatepleiotropicpath-
wayswasobserved.Together thepresent findings linkFADS1/2
activitywithASand identifyarachidonic acidashavinga likely
causal association with disease. Further investigation will be
needed to delineate the downstream processes that link the
FADS1 and FADS2 locus and arachidonic acid to aortic valve
abnormalities.
Our results point to the FADS1/2 locus and ω-6 fatty acid
biosynthesis aspotential therapeutic targets.Direct therapeu-
tic alterationofFADS1/2expression, tomimic theobservedge-
netic effects and reduce fatty acid desaturation, may repre-
sent a therapeutic strategy for AS, which is supported by the
results of ourmendelian randomization ofFADS1 expression.
Alternatively, we speculate that the role of FADS1/2 in the
conversion of linoleic acid to arachidonic acid raises the pos-
sibility of dietarymodification as apreventive strategy forAS.
Both approaches warrant further study as possible treat-
ments for AS.
Strengths and Limitations
Our discovery GWASwas performed in the GERA cohort with
one of the largest collections of cases with AS assembled to
date.Data fromseveral large-scalecohortsprovidedrobust rep-
lication for this novel association and extended it to relevant
fatty acid measures. Nonetheless, we note several limita-
tions. First, not all participants underwent echocardiogra-
phy, the criterion standard for diagnosing AS. We relied on a
heterogeneous definition of AS across cohorts that may not
have captured all cases, butmisclassification of undiagnosed
AScases as controls is likely tobias our results toward thenull,
as is heterogeneity in our definition of controls. Our use of
diagnosis and procedure codes to define AS also precludes an
assessment of disease severity.However, our case-finding ap-
proach permits the study of AS in large cohortswithout echo-
cardiographicdata, haspreviously led to thediscovery and ro-
bust replication of the LPA locus (including in many of the
cohorts in the present study2,4,5,9,10), and has a positive pre-
dictive value exceeding 90%.2We also observednoheteroge-
neity in ourmeta-analysis of rs174547, suggesting the various
definitions forASareconcordant.Second,somemendelianran-
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domization sensitivity analyses lacked statistical power, in-
cluding Egger regression, which is a known limitation of this
approach. Third, we restricted our GWAS to participantswith
self-reportedEuropean ancestry, because thenumber of non-
Europeanswas lowand the frequencyofFADS1/2variants var-
ies markedly across races/ethnicities.29 Fourth, although all
measured fatty acids were derived from blood, the measure-
ments were taken in red blood cells in the FOS cohort and in
plasma in theMESAcohort, andassociationswithAVC inboth
cohortswerecross-sectional.However, resultswerehighlycon-
sistent across the 2 cohorts despite the different approaches.
Fifth, we focused on the FADS1/2 genes as likely candidates
in the locus andprovide evidence in favor of this pathway.We
acknowledge that other genes nearby could also play a role,
but these are unlikely candidates based on their known biol-
ogy. In addition, although we observe modest reductions in
theodds ofAS amongparticipantswith 1 or 2 copies of themi-
nor allele, this reflects the natural genetic variation at a locus
with importantbiological function; targeting this locusbyphar-
macologicalmeanscouldachieve larger reductions in theodds
of AS.
Conclusions
We demonstrate that a common variant in the FADS1/2 locus
is associatedwithAS andAVC. Concordant findings frombio-
marker measurements and mendelian randomization link
increased ω-6 fatty acid biosynthesis to the development of
AS, which may represent a novel therapeutic target.
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